📊 AVCRF Key Takeaways
Is Avricore Health Inc. (AVCRF) a Good Investment?
Avricore Health Inc. presents an extremely high-risk profile due to complete absence of reportable financial data across all key metrics. With no revenue, no profitability, no balance sheet data, and zero insider activity, the company appears to be either pre-revenue, dormant, or non-operational. The lack of any measurable financial metrics makes fundamental analysis impossible and suggests either a shell company status or severe financial distress.
Avricore's fundamentals deteriorated sharply in 2025 after losing its major Shoppers Drug Mart relationship, with six-month revenue down 79% year over year to CAD 462,753 and comprehensive income swinging from a profit to a loss. The balance sheet is not highly levered and cash remains positive, but the business now needs to prove it can replace lost volume and restore sustainable gross profit without relying on customer concentration.
Why Buy Avricore Health Inc. Stock? AVCRF Key Strengths
- Operates in pharmaceutical sector which has potential for value creation if development stage
- No long-term financial debt reported, which reduces solvency pressure
- Still had positive working capital of about CAD 904,836 and cash of about CAD 855,190 at June 30, 2025
- 2024 showed meaningful revenue scaling and improving gross margin before the key customer loss
AVCRF Stock Risks: Avricore Health Inc. Investment Risks
- Complete absence of revenue and profitability data indicating non-operational status
- No measurable balance sheet metrics - inability to assess financial solvency or liquidity
- Zero insider activity suggesting lack of management confidence or engagement
- No data freshness - cannot determine if company is active or defunct
- Pharmaceutical development requires significant capital with high failure rates and extended time to commercialization
- Extreme customer concentration was exposed by the end of the Shoppers Drug Mart relationship, driving a severe revenue collapse
- Profitability has reversed, with Q2 2025 posting a gross loss and H1 2025 returning to net losses
- Operating cash flow turned negative in 2025, raising execution and funding risk if replacement revenue does not arrive quickly
Key Metrics to Watch
- Revenue recognition and cash generation milestones
- Balance sheet composition and working capital adequacy
- Clinical trial progression and regulatory approvals for product pipeline
- Quarterly revenue rebuild and customer diversification after the lost major account
- Operating cash flow burn relative to cash balance and working capital
Avricore Health Inc. (AVCRF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
AVCRF Profit Margin, ROE & Profitability Analysis
AVCRF vs Healthcare Sector: How Avricore Health Inc. Compares
How Avricore Health Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Avricore Health Inc. Stock Overvalued? AVCRF Valuation Analysis 2026
Based on fundamental analysis, Avricore Health Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Avricore Health Inc. Balance Sheet: AVCRF Debt, Cash & Liquidity
AVCRF Revenue Growth, EPS Growth & YoY Performance
AVCRF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Avricore Health Inc. (CIK: 0001355736)
❓ Frequently Asked Questions about AVCRF
What is the AI rating for AVCRF?
Avricore Health Inc. (AVCRF) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AVCRF's key strengths?
Claude: Operates in pharmaceutical sector which has potential for value creation if development stage. ChatGPT: No long-term financial debt reported, which reduces solvency pressure. Still had positive working capital of about CAD 904,836 and cash of about CAD 855,190 at June 30, 2025.
What are the risks of investing in AVCRF?
Claude: Complete absence of revenue and profitability data indicating non-operational status. No measurable balance sheet metrics - inability to assess financial solvency or liquidity. ChatGPT: Extreme customer concentration was exposed by the end of the Shoppers Drug Mart relationship, driving a severe revenue collapse. Profitability has reversed, with Q2 2025 posting a gross loss and H1 2025 returning to net losses.
What is AVCRF's revenue and growth?
Avricore Health Inc. reported revenue of N/A.
Does AVCRF pay dividends?
Avricore Health Inc. does not currently pay dividends.
Where can I find AVCRF SEC filings?
Official SEC filings for Avricore Health Inc. (CIK: 0001355736) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AVCRF's EPS?
Avricore Health Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AVCRF a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Avricore Health Inc. has a SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AVCRF stock overvalued or undervalued?
Valuation metrics for AVCRF: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AVCRF stock in 2026?
Our dual AI analysis gives Avricore Health Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AVCRF's free cash flow?
Avricore Health Inc.'s operating cash flow is N/A, with capital expenditures of N/A.
How does AVCRF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).